Lars Peter Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/997272/publications.pdf

Version: 2024-02-01

1305906 1113639 18 287 8 15 citations h-index g-index papers 18 18 18 413 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Are older adults insufficiently included in clinical trials?—An umbrella review. Basic and Clinical Pharmacology and Toxicology, 2021, 128, 213-223.	1.2	16
2	External validation of the Medication Risk Score in polypharmacy patients in general practice: A tool for prioritizing patients at greatest risk of potential drugâ€related problems. Basic and Clinical Pharmacology and Toxicology, 2021, 129, 319-331.	1.2	9
3	Effects of stratified medication review in high-risk patients at admission to hospital: a randomised controlled trial. Therapeutic Advances in Drug Safety, 2020, 11, 204209862095714.	1.0	9
4	Rivaroxaban Plasma Levels and Levetiracetam. Annals of Internal Medicine, 2020, 173, 771.	2.0	O
5	Evaluating the effect on asthma quality of life of added reflexology or homeopathy to conventional asthma management – an investigator-blinded, randomised, controlled parallel group study. European Clinical Respiratory Journal, 2020, 7, 1793526.	0.7	1
6	The impact of reflexology and homeopathy added to conventional asthma treatment on markers of airway inflammation $\hat{a} \in \hat{a}$ a randomised study. European Clinical Respiratory Journal, 2020, 7, 1726153.	0.7	O
7	Medication Review and Patient Outcomes in an Orthopedic Department: A Randomized Controlled Study. Journal of Patient Safety, 2018, 14, 74-81.	0.7	26
8	Pharmacokinetic Profile of Oral Magnesium Hydroxide. Basic and Clinical Pharmacology and Toxicology, 2017, 120, 264-269.	1.2	10
9	Risk of prescribing errors in acutely admitted patients: a pilot study. International Journal of Clinical Pharmacy, 2016, 38, 1157-1163.	1.0	5
10	Detection of Patients at High Risk of Medication Errors: Development and Validation of an Algorithm. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 143-149.	1.2	41
11	Response to Dr. Rutten's comment on "Serum magnesium and not vitamin D is associated with better QoL in COPD: A cross-sectional study― Respiratory Medicine, 2016, 112, 131.	1.3	O
12	Clinical Pharmacology in Denmark in 2016 – 40 Years with the Danish Society of Clinical Pharmacology and 20 Years as a Medical Speciality. Basic and Clinical Pharmacology and Toxicology, 2016, 119, 523-532.	1.2	12
13	Potentially inappropriate prescriptions in patients admitted to a psychiatric hospital. Nordic Journal of Psychiatry, 2016, 70, 365-373.	0.7	18
14	Number of drugs most frequently found to be independent risk factors for serious adverse reactions: a systematic literature review. British Journal of Clinical Pharmacology, 2015, 80, 808-817.	1.1	69
15	Serum magnesium and not vitamin D isÂassociated with better QoL in COPD: AÂcross-sectionalÂstudy. Respiratory Medicine, 2015, 109, 727-733.	1.3	11
16	Medication Counselling: Physicians' Perspective. Basic and Clinical Pharmacology and Toxicology, 2013, 113, 425-430.	1.2	7
17	SYSTEMIC EFFECTS OF INHALED FLUTICASONE PROPIONATE AND BUDESONIDE IN ADULT PATIENTS WITH ASTHMA. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 2115-2115.	2.5	1
18	Muscle mass and function in thyrotoxic patients before and during medical treatment. Clinical Endocrinology, 1999, 51, 693-699.	1.2	52